Related Experiment Videos
Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease
Insights
Interferon (IF) production is not defective in most chronic hepatitis B patients. However, patients with chronic inactive liver disease show a significantly weaker IF response, suggesting a potential difference in treatment efficacy.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic hepatitis B virus (HBV) liver disease is a significant global health concern.
- The role of interferon (IF) production in the immunopathogenesis of HBV infection remains incompletely understood.
- Previous hypotheses suggested a defect in IF production in chronic liver disease.
Purpose of the Study:
- To investigate and challenge the hypothesis of defective interferon production in chronic hepatitis B virus liver disease.
- To compare interferon production capacity across different stages of chronic hepatitis B and in healthy carriers.
Main Methods:
- Lymphocytes were isolated from patients with chronic active liver disease (CALD), chronic inactive liver disease (CILD), and healthy chronic carriers (HCC).
- Cells were stimulated with Newcastle Disease virus to assess interferon production.
- Interferon responses were compared between patient groups and healthy controls.
Main Results:
- Patients with CILD exhibited a significantly weaker interferon response compared to controls (P < 0.0005).
- Interferon production in CALD patients and HCC did not statistically differ from healthy controls.
- These findings suggest that the background for interferon treatment in CALD may not be entirely compromised.
Conclusions:
- Interferon production is generally preserved in chronic active liver disease and in healthy chronic carriers of hepatitis B.
- A defect in interferon production is evident in patients with chronic inactive liver disease.
- The results imply that interferon therapy for chronic active liver disease may not depend on a completely intact interferon production background.
Abstract:
To challenge the hypothesis that interferon (IF) production in chronic hepatitis-B virus liver disease is defective, lymphocytes from 14 patients with chronic active liver disease (CALD); from nine patients with chronic inactive liver disease (CILD), and from six healthy chronic carriers (HCC) were stimulated by Newcastle Disease virus. The patients with CILD showed a weak IF response by comparison with the controls (P less than 0.0005), whereas IF production by CALD patients and the HCC did not statistically differ from IF production in the healthy hepatitis-B surface antigen negative subjects who served as controls. These results indicate that IF treatment of CALD does not rely on a completely proved background.